Axsome Therapeutics (AXSM) Amortization - Intangibles (2022 - 2026)

Axsome Therapeutics has disclosed Amortization - Intangibles across 5 years of filings, most recently posting $1.6 million for Q1 2026.

• Amortization - Intangibles for Q1 2026 came in at $1.6 million, changed 0.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $6.4 million (changed 0.0% YoY), and the FY2025 annual result was $6.4 million, changed 0.27% from the prior year.
• Amortization - Intangibles came in at $1.6 million for Q1 2026 at Axsome Therapeutics, down from $1.6 million in the prior quarter.
• In the past five years, Amortization - Intangibles ranged from a high of $1.6 million in Q3 2022 to a low of $926000.0 in Q2 2022.
• The 5-year median for Amortization - Intangibles is $1.6 million (2024), against an average of $1.6 million.
• Across the five-year window, Amortization - Intangibles surged 71.6% in 2023 and declined 1.07% in 2025, its largest moves.
• Axsome Therapeutics' Amortization - Intangibles stood at $1.6 million in 2022, then changed by 0.0% to $1.6 million in 2023, then changed by 0.0% to $1.6 million in 2024, then changed by 0.0% to $1.6 million in 2025, then fell by 2.18% to $1.6 million in 2026.
• The last three Amortization - Intangibles figures came in at $1.6 million (Q1 2026), $1.6 million (Q4 2025), and $1.6 million (Q3 2025), per Business Quant data.